Daniel O'Day, CEO of Roche's pharma unit, declines to comment on Alexion deal talks, but says the company is keen on incorporating innovations into its portfolio.
Daniel O'Day, CEO of Roche, talks about the company's results for the first half of the year and sales of its new breast cancer drugs.
The chief executive of GlaxoSmithKline said the allegations of bribery and corruption in China were "deeply disappointing," as the company reported second-quarter results.
Glaxo's problems may go beyond the sales practices that are currently at the center of a bribery and corruption scandal in China. They may extend to its Shanghai research and development center.
British drug giant, GlaxoSmithKline admitted that some of its executives in China appear to have violated Chinese law in a bribery and corruption scandal.
GlaxoSmithKline CEO Andrew Witty will detail this week what action the drugmaker is taking in response to allegations of bribery against it in China, sources said.
China detained and questioned an executive of GlaxoSmithKline, amid an ongoing bribery investigation, reports CNBC's Eunice Yoon.
Chinese authorities are widening their net into allegations of bribery by drugmakers when officials visited Belgian pharmaceutical giant UCB on Thursday
China is raising the pressure on British drugmaker Glaxosmithkline in a very high-profile fight against corruption. CNBC's Eunice Yoon has this report.
China is barring a GlaxoSmithKline executive from leaving the country amid a widening $490 bribery scandal ensaring the drug giant.
China is preventing a GlaxoSmithKline executive from leaving the country as police accuse the British drugmaker of bribing officials and doctors, the drugmaker says.
CNBC's Eunice Yoon reports sales at the pharmaceutical giant jumped 20 percent last year but police say bribes may have spiked the gains.
Andrew Weiss, head of pharma and biotech research at Vontobel, , talks about Novartis' quarterly results and outlook and says the company will remain under pressure for the next few quarters.
Pharmaceutical and biotech stocks have outperformed markets this year, and with J&J's second-quarter earnings beat, investors may hope earnings will push stocks even higher.
China is using "concerted" probes of foreign baby formula, pharmaceutical and packaging companies to bolster domestic firms, according to observers.
Executives of British drug maker GlaxoSmithKline in China have confessed to charges of bribery and tax law violations, China's security ministry said on Thursday.
The trick to successful investing is knowing when to take profits and walk away. In this case, Cramer says it’s time.
Amgen's low-ball offer to Onyx Pharmaceuticals has set off speculation of a potential bidding war that could leave another company walking away with Onyx.
Onyx Pharmaceuticals has rejected a $10 billion takeover bid from Amgen, reports CNBC's Bertha Coombs.
Fast Money trader Jon Najarian takes a look at some unusual activity in shares of Onyx Pharmaceuticals. And a play on the biotechnolgy space, with the FMHR crew.